MyFinsight
Home
Blog
About
Contact
Accounts receivable, net
-$27,325K
Maturity of
available-for-sale securities
$27,337K
Accounts payable
$3,110K
Depreciation and
amortization
$2,584K
Stock-based compensation
$1,896K
Prepaid expenses and
other
-$116K
Other current assets
-$60K
Loss on disposal of
property and equipment
-$6K
Net cash provided by
operating activities
$15,416K
Net cash provided by
investing activities
$2,474K
Canceled cashflow
$19,681K
Canceled cashflow
$24,863K
Net increase
(decrease) in cash, cash...
$6,558K
Canceled cashflow
$11,332K
Accrued expenses and
other
-$11,694K
Net (loss) income
-$3,753K
Inventory, net
$3,178K
Operating lease assets and
liabilities, net
$553K
Post-marketing commitment
liability
-$503K
Purchase of
available-for-sale securities
$24,863K
Net cash used in
financing activities
-$11,332K
Payment of debt
$11,110K
Payment of exit costs
$222K
Back
Back
Cash Flow
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)
source: myfinsight.com